A nontoxic radiopharmaceutical that is used in RADIONUCLIDE IMAGING for the clinical evaluation of hepatobiliary disorders in humans.
The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, atomic number 43, and atomic weight 98.91. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.
A nontoxic radiopharmaceutical that is used in the clinical evaluation of hepatobiliary disorders in humans.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, liver, and spleen.
A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms.
A radiopharmaceutical used extensively in cholescintigraphy for the evaluation of hepatobiliary diseases. (From Int Jrnl Rad Appl Inst 1992;43(9):1061-4)
A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in cardiovascular and cerebral circulation.
A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.
Inorganic compounds that contain TECHNETIUM as an integral part of the molecule. Technetium 99m (m=metastable) is an isotope of technetium that has a half-life of about 6 hours. Technetium 99, which has a half-life of 210,000 years, is a decay product of technetium 99m.
Organic compounds that contain technetium as an integral part of the molecule. These compounds are often used as radionuclide imaging agents.
A trace element that is required in bone formation. It has the atomic symbol Sn, atomic number 50, and atomic weight 118.71.
A gamma-emitting RADIONUCLIDE IMAGING agent used in the evaluation of regional cerebral blood flow and in non-invasive dynamic biodistribution studies and MYOCARDIAL PERFUSION IMAGING. It has also been used to label leukocytes in the investigation of INFLAMMATORY BOWEL DISEASES.
A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.
A nontoxic radiopharmaceutical that is used in the diagnostic imaging of the renal cortex.
A technetium diagnostic aid used in renal function determination.
The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Compounds that contain the radical R2C=N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.

Duodenogastric reflux: clinical and therapeutic aspects. (1/40)

BACKGROUND: Duodenogastric reflux is believed to cause damage to gastric mucosa. Most reports on this disorder concern adult patients. PATIENTS AND METHODS: 1120 children with abdominal pain were studied; endoscopic features of duodenogastric reflux were found in 92 patients. To confirm the diagnosis of duodenogastric reflux, cholescintigraphy (Tc99-HEPIDA) was performed. Children with confirmed duodenogastric reflux by scintigraphy were given a prokinetic drug (cisapride). RESULTS: Endoscopic features of duodenogastric reflux were found in 92 children; the diagnosis was confirmed by scintigraphy in 59 patients. There was no significant difference in the severity of inflammation in gastric mucosa compared with the control group, whereas significantly fewer of these patients were infected with Helicobacter pylori. There was no correlation between regions of isotope accumulation and inflammatory lesions in the stomach. The prokinetic drug (cisapride) helped eliminate or greatly reduce duodenogastric reflux in children. CONCLUSIONS: When endoscopic features of duodenogastric reflux are found the final diagnosis should be based on an examination that does not itself influence the motility of the gastrointestinal tract: cholescintigraphy seems to be a useful method. However, because the use of milk as a test meal affects the scintigraphic image, there was no correlation between the area of isotope accumulation and the localisation of inflammatory lesions in the stomach. Duodenogastric reflux seems to be less important as a cause of inflammatory lesions than other factors (such as genetic predisposition, stress, etc). Prokinetic drugs have a beneficial influence on treatment results in children with inflammatory lesions of gastric mucosa with duodenogastric reflux.  (+info)

Outcome of endoscopic sphincterotomy in post cholecystectomy patients with sphincter of Oddi dysfunction as predicted by manometry and quantitative choledochoscintigraphy. (2/40)

BACKGROUND: Sphincter of Oddi dysfunction is diagnosed at manometry and, after cholecystectomy, non-invasively at quantitative choledochoscintigraphy. Patients may benefit from endoscopic sphincterotomy. AIMS: The aim of this study was to assess the usefulness of choledochoscintigraphy compared with manometry in predicting outcome of sphincterotomy in post cholecystectomy patients with sphincter of Oddi dysfunction. PATIENTS AND METHODS: Thirty patients with biliary-type pain complying with the Rome diagnostic criteria of sphincter of Oddi dysfunction and belonging to biliary group I and II were subjected to clinical evaluation, choledochoscintigraphic assessment of the hepatic hilum-duodenum transit time, endoscopic retrograde cholangiopancreatography, and perendoscopic manometry. Twenty two biliary group I and II patients with prolonged hepatic hilum-duodenum transit times were invited to undergo sphincterotomy. Fourteen patients underwent sphincterotomy; eight refused. Clinical and scintigraphic assessments were performed at follow up. RESULTS: Hepatic hilum-duodenum transit time was delayed in all patients with manometric evidence of sphincter of Oddi dysfunction, in all biliary group I patients and in 64% of biliary group II patients. At follow up, all patients who underwent sphincterotomy were symptom free and hepatic hilum-duodenum transit time had either normalised or significantly improved. A favourable post sphincterotomy outcome was predicted in 93% of cases at choledochoscintigraphy and in 57% at manometry. CONCLUSIONS: Quantitative choledochoscintigraphy is a useful and non-invasive test to diagnose sphincter of Oddi dysfunction as well as a reliable predictor of sphincterotomy outcome in post cholecystectomy biliary group I and II patients, irrespective of clinical classification and manometric findings.  (+info)

Hepatic clearance mechanism of Tc-99m-HIDA and its effect on quantitation of hepatobiliary function: Concise communication. (3/40)

Parameters affecting the hepatobiliary clearance of Tc-99m N(2,6-dimethylphenyl carbamoylmethyl) iminodiacetic acid (Tc-HIDA) were evaluated in dogs. Competitive clearance studies, were performed with Tc-HIDA after infusion to plasma saturation levels of an anion, sodium sulfobromophthalein (BSP), and a cation, oxyphenonium. The results demonstrated that Tc-HIDA is transported through hepatocytes by a carrier-mediated organic-anion pathway. The data are consistent with an alteration of the elimination kinetics of Tc-HIDA induced by elevations in the serum bilirubin level, and it is predicted that serum bilirubin at some increased concentration will dominate the distribution and elimination kinetics of Tc-HIDA independently of hepatobiliary status. A quantitative description of liver function in terms of regional distribution and elimination rate constants will require either a pharmacokinetic model that expressly includes the effects of bilirubin, the development of new anionic hepatobiliary agents capable of displacing endogenous bilirubin from transport binding sites, or the development of new hepatobiliary agents that use a different clearance mechanism from that used by bilirubin.  (+info)

Comparison of fatty meal and intravenous cholecystokinin infusion for gallbladder ejection fraction. (4/40)

Gallbladder ejection fraction (GBEF) measured with a fatty meal (half-and-half milk) was compared with that measured with 2 equal sequential intravenous infusions of cholecystokinin (CCK-8) in a paired study of healthy subjects. METHODS: GBEF was measured by (99m)Tc-hepatic iminodiacetic acid cholescintigraphy in 13 healthy subjects. Each subject received 2 sequential doses of CCK-8 (3 ng/kg/min for 10 min) on day 1, followed by, on day 2, a 240-mL (8 oz) fatty meal (half-and-half milk) per 70 kg of body weight. RESULTS: The mean +/- SD GBEF of 53.6% +/- 20.2% with fatty meal was significantly lower than the mean of 75.8% +/- 16.3% (P < 0.01) with the first dose of CCK-8 and 71.3% +/- 17.4% (P < 0.05) with the second dose. Fatty meal GBEF varied widely, from 23.5% to 91.8%. Percentile rankings of the fatty meal GBEF were determined as the preferred methodology for reporting results. Latent and ejection periods were significantly longer with fatty meal than with either dose of CCK-8. CONCLUSION: GBEF measured with fatty meal can serve as an alternative method to intravenous injection of CCK-8 when the hormone is no longer available for clinical use. The measurement of GBEF with fatty meal requires careful attention to the details of the meal and the measurement time sequence.  (+info)

Unique scintigraphic findings of bile extravasation in the presence of ascites: a complication of hepatic transplantation. (5/40)

A 99mTc-HIDA scan was performed on a 4-mo-old female, six days after hepatic transplantation. Gradually, a diffuse increase in activity was seen over the peritoneal region, consistent with a slow bile leak into ascitic fluid. Although the scintigraphic appearance of a bile leak has been previously described, it is usually seen as a focal area of extrabiliary activity. In this case, we report a pattern identified when the leak occurs in conjunction with ascites.  (+info)

Proposal of a modified scintigraphic method to evaluate duodenogastroesophageal reflux. (6/40)

Hepatobiliary scintigraphy with 99mTc-HIDA offers a noninvasive method to detect duodenogastric reflux. Biliary reflux was graded using the persistence rather than the intensity of the radioactive refluxate: Grade 0 was considered the absence of reflux, minimal reflux, or reflux in the first 10-15 min; Grade 1 was repetitive reflux lasting less than 10 min; Grade 2 was persistent reflux; and Grade 3 was reflux up to the esophagus. Twenty-five patients with foregut symptoms were studied and results were compared to 24-hr gastric pH monitoring. Scintigraphy and pH monitoring agreed in 15 out of 25 patients (60%), but no correlation was found with the endoscopic findings. The rationale for this approach is based on pathophysiologic evidence that damage to gastric and/or esophageal mucosa is mainly related to the prolonged contact time with duodenal contents. This technique seems to allow a complete functional evaluation of the esophagogastroduodenal tract without causing adjunctive irradiation or discomfort to the patient.  (+info)

Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man. (7/40)

Gall bladder storage of hepatic bile prevents complete recovery of biliary excretion of drugs to be obtained under physiological conditions in man. The aim of this study was to develop and validate a method for simultaneous measurement of gall bladder storage of a cholephilic drug, and of its duodenal excretion and t1/2 in bile. Duodenal perfusion using polyethylene glycol as intestinal recovery marker for measurement of drug duodenal excretion, with an iv bolus of 99mTc HIDA for measurement of drug mass within the gall bladder was used. Gall bladder volume was measured by ultrasonography. T1/2 in bile was measured by relating drug duodenal excretion to that of bile acid used as an endogenous bile marker. The use of bile acid as biliary marker was validated in two subjects receiving simultaneous iv infusion of indocyanine green. Seven healthy subjects were studied using a beta-lattam antibiotic, Cefotetan 1 g iv, as test drug. Median values during the study period (seven hours) were 51.1 mg for Cefotetan duodenal excretion, 45.2 mg for gall bladder mass and 2.8 mg/ml for concentration within the gall bladder. T1/2 of the drug in bile was 100 minutes. This technique enables measurement of mass and concentration of drugs within the gall bladder to be carried out, in addition to measurements of t1/2 of drugs in bile. These measurements may have specific application for assessment of potential efficacy of antibiotics in biliary tract infections, as well as general application for assessment of biliary excretory kinetics of drugs.  (+info)

HIDA scan in the follow-up of biliary-enteric anastomoses. (8/40)

In order to assess the patency and function of biliary-enteric anastomoses performed in our Department of Surgery, 21 patients entered the following study, provided an informed consent was obtained. All the patients were affected by benign biliary tract diseases and underwent either Roux-en-Y hepaticojejunostomy (11 cases), or side-to-side choledochoduodenostomy (10 cases). The 21 patients were evaluated with Tc-99m-HIDA scanning at intervals of 20 days-36 months after the surgical procedure (mean 14 months). The images were obtained after intravenous injection of the radioactive medium (5 mCi) and the scans were taken at 1 min (1 frame/s), 3 min (1 frame/10 s), and 56 min (1 frame/2 min). THe data were analyzed by a Digital PDP 11/34 Computer System. This method allowed us to assess each individual patient for the patency of the anastomosis and, by computer analysis, to build up a profile of the timing of the passage of the radioactive medium through the anastomosis, a delayed passage across the anastomosis was always pathological. In conclusion, the 99m-Tc-HIDA scanning used in our study for long-term follow-up of biliary-enteric anastomoses is reliable and allows an assessment of prognosis.  (+info)

Technetium Tc 99m Lidofenin is a radiopharmaceutical used in nuclear medicine imaging procedures, specifically for hepatobiliary scintigraphy. It is a technetium-labeled compound, where the radioisotope technetium-99m (^99m^Tc) is bound to lidofenin, a liver-imaging agent.

The compound is used to assess the function and anatomy of the liver, gallbladder, and biliary system. After intravenous administration, Technetium Tc 99m Lidofenin is taken up by hepatocytes (liver cells) and excreted into the bile ducts and ultimately into the small intestine. The distribution and excretion of this radiopharmaceutical can be monitored using a gamma camera, providing functional information about the liver and biliary system.

It is essential to note that the use of Technetium Tc 99m Lidofenin should be under the guidance and supervision of healthcare professionals trained in nuclear medicine, as its administration and handling require specific expertise and safety measures due to the radioactive nature of the compound.

Technetium is not a medical term itself, but it is a chemical element with the symbol Tc and atomic number 43. However, in the field of nuclear medicine, which is a branch of medicine that uses small amounts of radioactive material to diagnose or treat diseases, Technetium-99m (a radioisotope of technetium) is commonly used for various diagnostic procedures.

Technetium-99m is a metastable nuclear isomer of technetium-99, and it emits gamma rays that can be detected outside the body to create images of internal organs or tissues. It has a short half-life of about 6 hours, which makes it ideal for diagnostic imaging since it decays quickly and reduces the patient's exposure to radiation.

Technetium-99m is used in a variety of medical procedures, such as bone scans, lung scans, heart scans, liver-spleen scans, brain scans, and kidney scans, among others. It can be attached to different pharmaceuticals or molecules that target specific organs or tissues, allowing healthcare professionals to assess their function or identify any abnormalities.

Technetium Tc 99m Diethyl-iminodiacetic Acid (Tc 99m DTPA) is a radiopharmaceutical agent used in medical imaging. It is a technetium-labeled compound, where the radioisotope technetium-99m is bound to diethyl-iminodiacetic acid (DTPA). This complex is used as a renal agent for performing nuclear medicine imaging studies to assess kidney function and structure.

Technetium-99m is a metastable isotope of technetium that emits gamma rays, making it suitable for medical imaging. When Tc 99m DTPA is injected into the patient's body, it is excreted primarily by the kidneys through glomerular filtration and tubular secretion. The gamma rays emitted by technetium-99m are detected by a gamma camera, which generates images of the distribution and excretion of the radiopharmaceutical within the kidneys. This information helps physicians evaluate kidney function, detect abnormalities such as obstructions or tumors, and monitor the effectiveness of treatments.

It is essential to handle and administer Tc 99m DTPA with care due to its radioactive nature, following proper safety guidelines and regulations to ensure patient and staff safety.

Technetium Tc 99m Sulfur Colloid is a radioactive tracer used in medical imaging procedures, specifically in nuclear medicine. It is composed of tiny particles of sulfur colloid that are labeled with the radioisotope Technetium-99m. This compound is typically injected into the patient's body, where it accumulates in certain organs or tissues, depending on the specific medical test being conducted.

The radioactive emissions from Technetium Tc 99m Sulfur Colloid are then detected by a gamma camera, which produces images that can help doctors diagnose various medical conditions, such as liver disease, inflammation, or tumors. The half-life of Technetium-99m is approximately six hours, which means that its radioactivity decreases rapidly and is eliminated from the body within a few days.

Technetium Tc 99m Medronate is a radiopharmaceutical agent used in nuclear medicine for bone scintigraphy. It is a technetium-labeled bisphosphonate compound, which accumulates in areas of increased bone turnover and metabolism. This makes it useful for detecting and evaluating various bone diseases and conditions, such as fractures, tumors, infections, and arthritis.

The "Tc 99m" refers to the radioisotope technetium-99m, which has a half-life of approximately 6 hours and emits gamma rays that can be detected by a gamma camera. The medronate component is a bisphosphonate molecule that binds to hydroxyapatite crystals in bone tissue, allowing the radiolabeled compound to accumulate in areas of active bone remodeling.

Overall, Technetium Tc 99m Medronate is an important tool in nuclear medicine for diagnosing and managing various musculoskeletal disorders.

Technetium Tc 99m Disofenin is not a medical condition, but rather a radiopharmaceutical used in diagnostic imaging. It is a radioactive tracer used in nuclear medicine scans, specifically for liver and biliary system imaging. The compound consists of the radioisotope Technetium-99m (Tc-99m) bonded to the pharmaceutical Disofenin.

The Tc-99m is a gamma emitter with a half-life of 6 hours, making it ideal for diagnostic imaging. When administered to the patient, the compound is taken up by the liver and excreted into the bile ducts and gallbladder, allowing medical professionals to visualize these structures using a gamma camera. This can help detect various conditions such as tumors, gallstones, or obstructions in the biliary system.

It's important to note that Technetium Tc 99m Disofenin is used diagnostically and not for therapeutic purposes. The radiation exposure from this compound is generally low and considered safe for diagnostic use. However, as with any medical procedure involving radiation, the benefits and risks should be carefully weighed and discussed with a healthcare professional.

Technetium Tc 99m Pyrophosphate (Tc-99m PYP) is a radiopharmaceutical agent used in nuclear medicine imaging, specifically myocardial perfusion imaging. It is a complex of technetium-99m, a metastable isotope of technetium, with pyrophosphate, a molecule that accumulates in damaged heart muscle tissue.

When injected into the patient's bloodstream, Tc-99m PYP is taken up by the heart muscle in proportion to its blood flow and the degree of damage or scarring (fibrosis). This allows for the detection and evaluation of conditions such as myocardial infarction (heart attack), cardiomyopathy, and heart transplant rejection.

The imaging procedure involves the injection of Tc-99m PYP, followed by the acquisition of images using a gamma camera, which detects the gamma rays emitted by the technetium-99m isotope. The resulting images provide information about the distribution and extent of heart muscle damage, helping physicians to make informed decisions regarding diagnosis and treatment planning.

Technetium Tc 99m Aggregated Albumin is a radiopharmaceutical preparation used in diagnostic imaging. It consists of radioactive technetium-99m (^99m^Tc) chemically bonded to human serum albumin, which has been aggregated to increase its size and alter its clearance from the body.

The resulting compound is injected into the patient's bloodstream, where it accumulates in the reticuloendothelial system (RES), including the liver, spleen, and bone marrow. The radioactive emission of technetium-99m can then be detected by a gamma camera, producing images that reflect the distribution and function of the RES.

This imaging technique is used to diagnose and monitor various conditions, such as liver disease, inflammation, or tumors. It provides valuable information about the patient's health status and helps guide medical decision-making.

Technetium Tc 99m Pentetate is a radioactive pharmaceutical preparation used as a radiopharmaceutical agent in medical imaging. It is a salt of technetium-99m, a metastable nuclear isomer of technetium-99, which emits gamma rays and has a half-life of 6 hours.

Technetium Tc 99m Pentetate is used in various diagnostic procedures, including renal imaging, brain scans, lung perfusion studies, and bone scans. It is distributed throughout the body after intravenous injection and is excreted primarily by the kidneys, making it useful for evaluating renal function and detecting abnormalities in the urinary tract.

The compound itself is a colorless, sterile, pyrogen-free solution that is typically supplied in a lead shielded container to protect against radiation exposure. It should be used promptly after preparation and handled with care to minimize radiation exposure to healthcare workers and patients.

Technetium compounds refer to chemical substances that contain the radioactive technetium (Tc) element. Technetium is a naturally rare element and does not have any stable isotopes, making it only exist in trace amounts in the Earth's crust. However, it can be produced artificially in nuclear reactors.

Technetium compounds are widely used in medical imaging as radioactive tracers in diagnostic procedures. The most common technetium compound is Technetium-99m (Tc-99m), which has a half-life of 6 hours and emits gamma rays that can be detected by external cameras. Tc-99m is often bound to various pharmaceuticals, such as methylene diphosphonate (MDP) or human serum albumin (HSA), to target specific organs or tissues in the body.

Technetium compounds are used in a variety of diagnostic procedures, including bone scans, lung perfusion scans, myocardial perfusion imaging, and brain scans. They provide valuable information about organ function, blood flow, and tissue metabolism, helping doctors diagnose various medical conditions such as cancer, heart disease, and bone fractures.

It is important to note that technetium compounds should only be used under the supervision of trained medical professionals due to their radioactive nature. Proper handling, administration, and disposal procedures must be followed to ensure safety and minimize radiation exposure.

Organotechnetium compounds are chemical substances that contain carbon-technetium bonds, where technetium is an element with the symbol Tc and atomic number 43. These types of compounds are primarily used in medical imaging as radioactive tracers due to the ability of technetium-99m to emit gamma rays. The organotechnetium compounds help in localizing specific organs, tissues, or functions within the body, making them useful for diagnostic purposes in nuclear medicine.

It is important to note that most organotechnetium compounds are synthesized from technetium-99m, which is generated from the decay of molybdenum-99. The use of these compounds requires proper handling and administration by trained medical professionals due to their radioactive nature.

I'm sorry for any confusion, but "Tin" does not have a medical definition. Tin is a chemical element with the symbol Sn and atomic number 50. It is a malleable, ductile, silvery-white post-transition metal. It is found in nature mainly as tin oxides and is obtained from the mineral cassiterite through mining and processing.

Tin has no known biological role in humans, animals, or plants, and it is not considered an essential nutrient. Small amounts of tin can be found in some foods and drinking water, but these levels are generally low and not considered harmful. High levels of tin can be toxic to the human body, causing symptoms such as nausea, vomiting, and diarrhea.

If you have any questions about a medical condition or treatment, I would recommend consulting with a healthcare professional for accurate information and guidance.

Technetium Tc 99m Exametazime is a radiopharmaceutical agent used in nuclear medicine imaging procedures. The compound consists of the radioisotope Technetium-99m (^99m^Tc) bonded to Exametazime, also known as HMPAO (hexamethylpropyleneamine oxime).

Once injected into the patient's bloodstream, Technetium Tc 99m Exametazime distributes evenly throughout the brain, crossing the blood-brain barrier and entering cells. The radioactive decay of Technetium-99m emits gamma rays that can be detected by a gamma camera, creating images of the brain's blood flow and distribution of the tracer.

This imaging technique is often used in cerebral perfusion studies to assess conditions such as stroke, epilepsy, or dementia, providing valuable information about regional cerebral blood flow and potential areas of injury or abnormality.

Technetium Tc 99m Sestamibi is a radiopharmaceutical compound used in medical imaging, specifically in myocardial perfusion scintigraphy. It is a technetium-labeled isonitrile chelate that is taken up by mitochondria in cells with high metabolic activity, such as cardiomyocytes (heart muscle cells).

Once injected into the patient's body, Technetium Tc 99m Sestamibi emits gamma rays, which can be detected by a gamma camera. This allows for the creation of images that reflect the distribution and function of the radiopharmaceutical within the heart muscle. The images can help identify areas of reduced blood flow or ischemia, which may indicate coronary artery disease.

The uptake of Technetium Tc 99m Sestamibi in other organs, such as the breast and thyroid, can also be used for imaging purposes, although its primary use remains in cardiac imaging.

Technetium Tc 99m Dimercaptosuccinic Acid (DMSA) is a radiopharmaceutical agent used in nuclear medicine imaging procedures. The compound is made up of the radioisotope Technetium-99m, which emits gamma rays that can be detected by a gamma camera, and dimercaptosuccinic acid, which binds to certain types of metal ions in the body.

In medical imaging, Technetium Tc 99m DMSA is typically used to visualize the kidneys and detect any abnormalities such as inflammation, infection, or tumors. The compound is taken up by the renal tubules in the kidneys, allowing for detailed images of the kidney structure and function to be obtained.

It's important to note that the use of Technetium Tc 99m DMSA should be under the supervision of a trained medical professional, as with any radiopharmaceutical agent, due to the radiation exposure involved in its use.

Technetium Tc 99m Mertiatide is a radiopharmaceutical used in nuclear medicine imaging procedures. It is a technetium-labeled compound, where the radioisotope technetium-99m (^99m^Tc) is bound to mercaptoacetyltriglycine (MAG3). The resulting complex is known as ^99m^Tc-MAG3 or Technetium Tc 99m Mertiatide.

This radiopharmaceutical is primarily used for renal function assessment, including evaluation of kidney blood flow, glomerular filtration rate (GFR), and detection of renal obstructions or other abnormalities. After intravenous administration, Technetium Tc 99m Mertiatide is rapidly excreted by the kidneys, allowing for visualization and quantification of renal function through gamma camera imaging.

It's important to note that the use of radiopharmaceuticals should be performed under the guidance of a qualified healthcare professional, as they involve the administration of radioactive materials for diagnostic purposes.

Radionuclide imaging, also known as nuclear medicine, is a medical imaging technique that uses small amounts of radioactive material, called radionuclides or radiopharmaceuticals, to diagnose and treat various diseases and conditions. The radionuclides are introduced into the body through injection, inhalation, or ingestion and accumulate in specific organs or tissues. A special camera then detects the gamma rays emitted by these radionuclides and converts them into images that provide information about the structure and function of the organ or tissue being studied.

Radionuclide imaging can be used to evaluate a wide range of medical conditions, including heart disease, cancer, neurological disorders, gastrointestinal disorders, and bone diseases. The technique is non-invasive and generally safe, with minimal exposure to radiation. However, it should only be performed by qualified healthcare professionals in accordance with established guidelines and regulations.

Sodium Pertechnetate Tc 99m is a radioactive pharmaceutical preparation used in medical diagnostic imaging. It is a technetium-99m radiopharmaceutical, where technetium-99m is a metastable nuclear isomer of technetium-99, which emits gamma rays and has a half-life of 6 hours. Sodium Pertechnetate Tc 99m is used as a contrast agent in various diagnostic procedures, such as imaging of the thyroid, salivary glands, or the brain, to evaluate conditions like inflammation, tumors, or abnormalities in blood flow. It is typically administered intravenously, and its short half-life ensures that the radiation exposure is limited.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Oximes are a class of chemical compounds that contain the functional group =N-O-, where two organic groups are attached to the nitrogen atom. In a clinical context, oximes are used as antidotes for nerve agent and pesticide poisoning. The most commonly used oxime in medicine is pralidoxime (2-PAM), which is used to reactivate acetylcholinesterase that has been inhibited by organophosphorus compounds, such as nerve agents and certain pesticides. These compounds work by forming a bond with the phosphoryl group of the inhibited enzyme, allowing for its reactivation and restoration of normal neuromuscular function.

... technetium tc 99m disofenin MeSH D12.125.072.401.900 - technetium tc 99m lidofenin MeSH D12.125.072.415 - isodesmosine MeSH ... technetium tc 99m diethyl-iminodiacetic acid MeSH D12.125.072.401.840 - ...
... technetium tc 99m exametazime MeSH D02.691.825.710 - technetium tc 99m lidofenin MeSH D02.691.825.750 - technetium tc 99m ... technetium tc 99m mertiatide MeSH D02.691.825.875 - technetium tc 99m pentetate MeSH D02.691.825.937 - technetium tc 99m ... technetium tc 99m disofenin MeSH D02.241.081.583.900 - technetium tc 99m lidofenin MeSH D02.241.081.751.650 - procetofen MeSH ... technetium tc 99m disofenin MeSH D02.491.485.900 - technetium tc 99m lidofenin MeSH D02.491.567.249 - imino furanoses MeSH ...
... technetium tc 99m disofenin MeSH D12.125.072.401.900 - technetium tc 99m lidofenin MeSH D12.125.072.415 - isodesmosine MeSH ... technetium tc 99m diethyl-iminodiacetic acid MeSH D12.125.072.401.840 - ...
Technetium Tc 99m Lidofenin. A nontoxic radiopharmaceutical that is used in RADIONUCLIDE IMAGING for the clinical evaluation of ... OpiumTechnetium Tc 99m LidofeninBilirubinBile Acids and SaltsGlucuronosyltransferaseUrsodeoxycholic AcidCholesterol ... Gallbladder NeoplasmsCystic DuctAnthracosilicosisCholangiographyOpiumBiliary FistulaTechnetium Tc 99m LidofeninBilirubinSitus ... Technetium (99mTc) mebrofenin. Decreased GBEF may be indicative of asymptomatic cholelithiasis, which is usually without ...
Technetium Tc 99m Disofenin. *Technetium Tc 99m Exametazime. *Technetium Tc 99m Lidofenin ... "Technetium Tc 99m Exametazime" by people in this website by year, and whether "Technetium Tc 99m Exametazime" was a major or ... Technetium Tc 99m Aggregated Albumin. *Technetium Tc 99m Diethyl-iminodiacetic Acid. *Technetium Tc 99m Dimercaptosuccinic Acid ... "Technetium Tc 99m Exametazime" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
99mTc-Lidofenin use Technetium Tc 99m Lidofenin 99mTc-MAG3 use Technetium Tc 99m Mertiatide ... 99mTc-Diethyl IDA use Technetium Tc 99m Diethyl-iminodiacetic Acid 99mTc-Dimercaptosuccinic Acid use Technetium Tc 99m ... 99mTc-Hexamibi use Technetium Tc 99m Sestamibi ... 99mTc-Sestamibi use Technetium Tc 99m Sestamibi 99Tc-Succimer ... 99mTc-DMSA use Technetium Tc 99m Dimercaptosuccinic Acid ...
99mTc-Lidofenin use Technetium Tc 99m Lidofenin 99mTc-MAG3 use Technetium Tc 99m Mertiatide ... 99mTc-Diethyl IDA use Technetium Tc 99m Diethyl-iminodiacetic Acid 99mTc-Dimercaptosuccinic Acid use Technetium Tc 99m ... 99mTc-Hexamibi use Technetium Tc 99m Sestamibi ... 99mTc-Sestamibi use Technetium Tc 99m Sestamibi 99Tc-Succimer ... 99mTc-DMSA use Technetium Tc 99m Dimercaptosuccinic Acid ...
99mTc-Lidofenin use Technetium Tc 99m Lidofenin 99mTc-MAG3 use Technetium Tc 99m Mertiatide ... 99mTc-Diethyl IDA use Technetium Tc 99m Diethyl-iminodiacetic Acid 99mTc-Dimercaptosuccinic Acid use Technetium Tc 99m ... 99mTc-Hexamibi use Technetium Tc 99m Sestamibi ... 99mTc-Sestamibi use Technetium Tc 99m Sestamibi 99Tc-Succimer ... 99mTc-DMSA use Technetium Tc 99m Dimercaptosuccinic Acid ...
99mTc-Lidofenin use Technetium Tc 99m Lidofenin 99mTc-MAG3 use Technetium Tc 99m Mertiatide ... 99mTc-Diethyl IDA use Technetium Tc 99m Diethyl-iminodiacetic Acid 99mTc-Dimercaptosuccinic Acid use Technetium Tc 99m ... 99mTc-Hexamibi use Technetium Tc 99m Sestamibi ... 99mTc-Sestamibi use Technetium Tc 99m Sestamibi 99Tc-Succimer ... 99mTc-DMSA use Technetium Tc 99m Dimercaptosuccinic Acid ...
Technetium Tc 99m Lidofenin Actions. * Search in PubMed * Search in MeSH * Add to Search ... Use of a (99m)Tc-HIDA recovery marker permitted the absolute mass of unconjugated bile acids in the gallbladder to be ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
99m-Tc-Lidofenin 99mTc-HIDA 99mTc-Lidofenin Tc-99m Lidofenin Technetium Tc 99m 2,6-Dimethyl Iminodiacetic Acid Technetium-99m- ... Technetium Tc 99m Lidofenin Preferred Term Term UI T058784. Date01/01/1999. LexicalTag ABX. ThesaurusID ... Technetium Tc 99m Lidofenin. Tree Number(s). D02.241.081.583.900. D02.491.485.900. D02.691.825.710. D12.125.072.401.900. Unique ... Technetium Tc 99m Lidofenin Preferred Concept UI. M0029344. Registry Number. 6433TZJ6TQ. Scope Note. A nontoxic ...
99m-Tc-Lidofenin 99mTc-HIDA 99mTc-Lidofenin Tc-99m Lidofenin Technetium Tc 99m 2,6-Dimethyl Iminodiacetic Acid Technetium-99m- ... Technetium Tc 99m Lidofenin Preferred Term Term UI T058784. Date01/01/1999. LexicalTag ABX. ThesaurusID ... Technetium Tc 99m Lidofenin. Tree Number(s). D02.241.081.583.900. D02.491.485.900. D02.691.825.710. D12.125.072.401.900. Unique ... Technetium Tc 99m Lidofenin Preferred Concept UI. M0029344. Registry Number. 6433TZJ6TQ. Scope Note. A nontoxic ...
99mTc-Lidofenin Lidofenin, Tc-99m Tc 99m Lidofenin Tc-99m Lidofenin Technetium 99m Lidofenin Technetium Tc 99m 2,6 Dimethyl ... 99mTc-Lidofenin. Lidofenin, Tc-99m. Tc 99m Lidofenin. Tc-99m Lidofenin. Technetium 99m Lidofenin. Technetium Tc 99m 2,6 ... Technetium Tc 99m Lidofenin Entry term(s). 99m Tc Lidofenin 99m-Tc-Lidofenin 99mTc HIDA 99mTc Lidofenin 99mTc-HIDA ... 99m Tc Lidofenin. 99m-Tc-Lidofenin. 99mTc HIDA. 99mTc Lidofenin. 99mTc-HIDA. ...
Technetium Tc^99m^ lidofenin Current Synonym true false 3653730010 Technetium (99m-Tc) lidofenin Current Synonym true false ... Technetium Tc^99c^ lidofenin Current Synonym true false 2817215016 ... Technetium (99m-Tc) lidofenin (substance). Code System Preferred Concept Name. Technetium (99m-Tc) lidofenin (substance). ...
Tc 99m Lidofenin N0000166767 Technetium Tc 99m Medronate N0000170314 Technetium Tc 99m Mertiatide N0000166768 Technetium Tc 99m ... Pentetate N0000166195 Technetium Tc 99m Pyrophosphate N0000166769 Technetium Tc 99m Sestamibi N0000166203 Technetium Tc 99m ... Technetium Tc 99m Aggregated Albumin N0000170258 Technetium Tc 99m Diethyl-iminodiacetic Acid N0000166770 Technetium Tc 99m ... Acid N0000006863 Technetium Tc 99m Disofenin N0000166771 Technetium Tc 99m Exametazime N0000170259 Technetium ...
Tc 99m Disofenin Technetium Tc 99m Exametazime Technetium Tc 99m Lidofenin Technetium Tc 99m Medronate Technetium Tc 99m ... Mertiatide Technetium Tc 99m Pentetate Technetium Tc 99m Pyrophosphate Technetium Tc 99m Sestamibi Technetium Tc 99m Sulfur ... Technetium Compounds Technetium Tc 99m Aggregated Albumin Technetium Tc 99m Diethyl-iminodiacetic Acid Technetium Tc 99m ... Sodium Ionophores Sodium Isotopes Sodium Lactate Sodium Morrhuate Sodium Nitrite Sodium Oxybate Sodium Pertechnetate Tc 99m ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
D1.632.825.475 Technetium Tc 99m Exametazime D1.632.825.562 Technetium Tc 99m Lidofenin D1.632.825.710 Technetium Tc 99m ... D1.632.825.750 Technetium Tc 99m Mertiatide D1.632.825.775 Technetium Tc 99m Pentetate D1.632.825.875 Technetium Tc 99m ... D4.345.349.810 Technetium Tc 99m Aggregated Albumin D1.632.825.375 Technetium Tc 99m Diethyl-iminodiacetic Acid D1.632.825.445 ... Technetium Tc 99m Dimercaptosuccinic Acid D1.632.825.468 Technetium Tc 99m Disofenin ...
Technetium Tc 99m Disofenin [D02.241.081.583.450] * Technetium Tc 99m Lidofenin [D02.241.081.583.900] ... Technetium Tc 99m Diethyl-iminodiacetic Acid [D02.241.081.583.400] * ... Technetium Tc 99m Disofenin [D12.125.072.401.840] * Technetium Tc 99m Lidofenin [D12.125.072.401.900] ... Technetium Tc 99m Diethyl-iminodiacetic Acid [D12.125.072.401.830] * ...
99m compounds such as mebrofenin, disofenin, lidofenin, bisicate, and exametazime for the photon energy range from 8 to 32 keV ... Technetium (Tc) Atomic Data for Technetium (Tc) Atomic Number = 43 Atomic Weight = 98.9062 Reference E95 There are over 100 ... technetium-99m were built in the atomic structure the technetium mass number activation of molybdenum-98 to form technetium-99m ... technetium-98 with 4.2 million years, and technetium-99 with 211,100 years. They isolated the metastable isotope technetium-99m ...
Technetium Tc 99m Exametazime [D02.691.825.562] * Technetium Tc 99m Lidofenin [D02.691.825.710] ... Tc 99m-Albumin Tc 99m-Albumin Colloid Tc-99m-HAM Tc-99m-MAA Tc-99m-Microalbumin Tc-HAMM Tc99m-Albumin Technetium-99m Albumin ... Tc 99m-Albumin Broader Concept UI. M0021096. Registry Number. 0. Terms. Tc 99m-Albumin Preferred Term Term UI T040163. Date06/ ... Technetium Tc 99m Aggregated Albumin Preferred Term Term UI T040159. Date01/01/1999. LexicalTag ABX. ThesaurusID NLM (1985). ...

No FAQ available that match "technetium tc 99m lidofenin"

No images available that match "technetium tc 99m lidofenin"